Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Sysco Corp.
SYYConsumer StaplesGenerated Jul 5, 2026, 08:13 PM UTC
SYY (Sysco Corp.) analytical snapshot. Revenue grew +11.2% YoY to $76.33B. Net margin at 2.32% (expanding ▲). Return on equity 128.08%, ROA 7.76%, ROIC 219.90%. Market cap $40.56B at $84.83 per share. Trailing P/E 24.45, P/S 0.53, P/B 17.66. EV/Operating income ≈ 16.21 (EV $49.25B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -10 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Market cap
$40.56B
478.18M shares
Price
$84.83
NYQ
P/E (ttm)
24.45
Revenue (FY)
$76.33B
YoY +11.2%
Net margin
2.32%
▲ 1.91pp
Free cash flow
$2.08B
2.72% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 15Stable
80% conf
Revenue grew +11.2% YoY to $76.33B. Net margin at 2.32% (expanding ▲). Return on equity 128.08%, ROA 7.76%, ROIC 219.90%.
- Revenue grew +11.2% YoY to $76.33B.
- Net margin at 2.32% (expanding ▲).
- Return on equity 128.08%, ROA 7.76%, ROIC 219.90%.
- Gross margin 18.28%, operating margin 3.98%.
- Free cash flow margin 2.72% ($2.08B).
- Net income up ▲ +30.2% YoY.
- Debt/equity 4.61, current ratio 1.33, net debt $8.69B.
- Asset turnover 2.73 — capital efficiency.
Revenue (FY)
$76.33B
YoY +11.2%
Net margin
2.32%
▲ 1.91pp
ROE
128.08%
ROA 7.76%
ROIC
219.90%
EPS (diluted)
$3.47
FY2025
Free cash flow
$2.08B
2.72% margin
Debt / equity
4.61
Cash $1.90B
Current ratio
1.33
Equity $2.30B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | — | 0.00 |
| 2017 | — | — | — | — | — | $1.01B | 0.00 |
| 2018 | — | — | — | — | — | $1.46B | 0.00 |
| 2019 | $55.37B | — | 19.07 | 3.71 | 0.00 | $1.55B | 0.00 |
| 2020 | $58.73B | +6.1% | 18.88 | 3.94 | 0.00 | $1.47B | 0.00 |
| 2021 | $60.11B | +2.4% | 18.98 | 3.88 | 0.00 | $1.72B | 0.00 |
| 2022 | $52.89B | -12.0% | 18.72 | 1.42 | 0.41 | $898.3M | 8.61 |
| 2023 | $51.30B | -3.0% | 18.24 | 2.82 | 1.02 | $1.43B | 45.24 |
| 2024 | $68.64B | +33.8% | 17.95 | 3.42 | 1.98 | $1.16B | 87.51 |
| 2025 | $76.33B | +11.2% | 18.28 | 3.98 | 2.32 | $2.08B | 128.08 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 29, 2025 | $19.60B | — | — | 6.62% |
| Sep 27, 2025 | $21.15B | — | +7.9% | 2.25% |
| Dec 27, 2025 | $41.91B | — | +98.2% | 2.07% |
| Dec 27, 2025 | $20.76B | — | -50.5% | 4.17% |
| Mar 28, 2026 | $62.43B | — | +200.7% | 1.93% |
| Mar 28, 2026 | $20.52B | — | -67.1% | 5.88% |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 0
2019: 55,371
2020: 58,727
2021: 60,114
2022: 52,893
2023: 51,298
2024: 68,636
2025: 76,325
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 0
2017: 1,013
2018: 1,461
2019: 1,546
2020: 1,468
2021: 1,719
2022: 898
2023: 1,433
2024: 1,158
2025: 2,075
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 20Improving
80% conf
Latest annual report (10-K) filed Aug 22, 2025. Latest quarterly report (10-Q) filed Apr 29, 2026. 15 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Aug 22, 2025.
- Latest quarterly report (10-Q) filed Apr 29, 2026.
- 15 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Sysco Corp.; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 20 recent 13G passive institutional ownership notices.
Latest 10-K
Aug 22, 2025
Annual report
Latest 10-Q
Apr 29, 2026
8-K (recent)
15
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 8, 2001 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Nov 2, 2001 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 11, 2004 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jul 2, 2026 | 8-K | FORM 8-K |
| May 18, 2026 | 8-K | FORM 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Apr 20, 2026 | 8-K | 8-K |
| Apr 2, 2026 | 8-K | 8-K |
| Mar 30, 2026 | 8-K | FORM 8-K |
| Mar 30, 2026 | 8-K | FORM 8-K |
| Mar 5, 2026 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -76Deteriorating
64% conf
5 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
- Leverage is building — debt rising while equity contracts: Long-term debt grew +58.9% while stockholders equity declined -11.0%. The debt-to-equity ratio is deteriorating, increasing financial risk and interest burden. This may constrain future borrowing capacity.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 7 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- Operating cash flow exceeds net income: OCF is 1.62x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
- 3 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 4 new risk-language term(s) detected in filing text: Going concern doubt, Substantial doubt about ability to continue, Restatement of financial statements, Impairment charge.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$76.33B
+11.2% YoY
Gross profit
$13.96B
+13.3% YoY
Operating income
$3.04B
+29.5% YoY
Net income
$1.77B
+30.2% YoY
Operating cash flow
$2.87B
+60.1% YoY
Capex
$793.0M
+25.3% YoY
Total assets
$22.82B
+3.3% YoY
Long-term debt
$12.90B
+58.9% YoY
Filing quality score
76/100
3 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $68.64B | $76.33B | $7.69B | +11.2% |
| Gross profit | $12.32B | $13.96B | $1.64B | +13.3% |
| Operating income | $2.35B | $3.04B | $693.0M | +29.5% |
| Net income | $1.36B | $1.77B | $411.0M | +30.2% |
| Operating cash flow | $1.79B | $2.87B | $1.08B | +60.1% |
| Capex | $633.0M | $793.0M | $160.0M | +25.3% |
| Total assets | $22.09B | $22.82B | $735.0M | +3.3% |
| Long-term debt | $8.12B | $12.90B | $4.78B | +58.9% |
| Cash & equivalents | $867.0M | $745.0M | $-122.0M | -14.1% |
| Stockholders equity | $1.55B | $1.38B | $-171.0M | -11.0% |
| Inventory | $1.65B | $1.77B | $120.9M | +7.3% |
| Interest expense | $125.5M | $118.3M | $-7.2M | -5.7% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | AssetsFairValueDisclosure, CashAndCashEquivalentsFairValueDisclosure, FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear |
| Removed | AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue, CapitalizedComputerSoftwareGross, CashSurrenderValueOfLifeInsurance, CurrentIncomeTaxExpenseBenefit, DebtAndCapitalLeaseObligations, DeferredIncomeTaxExpenseBenefit, DeferredIncomeTaxLiabilities, DeferredTaxAssetInterestCarryforward, DeferredTaxAssetsGross |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 7 | 0 | NEW |
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Substantial doubt about ability to continue | high | 3 | 0 | NEW |
| Restatement of financial statements | high | 2 | 0 | NEW |
| Impairment charge | medium | 11 | 0 | NEW |
| Restructuring | medium | 76 | 9 | Ongoing |
| Off-balance sheet arrangements | medium | 22 | 2 | Ongoing |
| Related party transactions | low | 9 | 0 | NEW |
Filing signal breakdown
Red flags: 5
Positive: 1
Watch: 1
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $40.56B at $84.83 per share.
- ProPrice & TechnicalsPrice $84.83 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -10
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Sysco Corp. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewPrice $84.83 — uptrend (above 200-DMA); 1-month momentum positive..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow SYY stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Sysco Corp. SYY● you | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |